OncoMatch/Clinical Trials/NCT05977673
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Is NCT05977673 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tislelizumab for hodgkin lymphoma.
Treatment: Tislelizumab — This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hodgkin Lymphoma
Disease stage
Excluded: Stage IA WITHOUT A LARGE TUMOR BURDEN
all stages except IA without a large tumor burden
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: any previous treatment for HL
Any previous treatment (including radiation therapy) for HL
Lab requirements
Blood counts
ANC > 1 x 10^9/L (without growth factor support within 7 days of ANC measurement), unless due to bone marrow involvement by lymphoma; Platelet > 50 x 10^9/L (without growth factor support or transfusion within 7 days of platelets measurement), unless due to bone marrow involvement by lymphoma; Hemoglobin > 8 g/dL (prior transfusion is acceptable)
Kidney function
Creatinine clearance ≥ 30 ml/min (Cockcroft-Gault or measured)
Liver function
AST/ALT ≤ 3.0 × ULN; Serum total bilirubin < 1.5 × ULN (or < 3 x ULN in case of documented Gilbert's syndrome)
Adequate organ and marrow function as defined below: - ANC > 1x10^9/L (without growth factor support within 7 days of ANC measurement), unless due to bone marrow involvement by lymphoma - Platelet > 50 x 10^9/L (without growth factor support or transfusion within 7 days of platelets measurement), unless due to bone marrow involvement by lymphoma - Hemoglobin > 8 g/dL (prior transfusion is acceptable) - Creatinine clearance ≥ 30 ml/min (Cockcroft-Gault or measured) - AST/ALT ≤ 3.0 × ULN - Serum total bilirubin < 1.5 × ULN (or < 3 x ULN in case of documented Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05977673 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages